Parexel to be acquired by Pamplona Capital for $5 billion

Biopharmaceutical company Parexel confirmed Tuesday morning it will be acquired by Pamplona Capital for $88.10 per share in cash, in a transaction valued at approximately $5 billion.

from Mergers and Acquisitions http://ift.tt/2rML3YN